■Yuhan Corporation announced on the 12th that it has unveiled the 2025 version of its magnesium supplement "Magvispeed," a liquid formulation of "Magvi." This advertisement contains the messages "When you need Magvispeed" and "Quickly effective as medicine." It conveys that the liquid form of the over-the-counter medicine Magvispeed demonstrates rapid efficacy in situations such as muscle cramps, physical fatigue, and decreased stamina resulting from magnesium deficiency that can occur in daily life. Magvispeed contains 1200 mg of glycerophosphate magnesium, which is among various types of magnesium. This magnesium can only be included in medicinal products and minimizes common diarrhea side effects associated with magnesium. The liquid form allows for rapid absorption, making it easy to take even when tablets or capsules are difficult to consume. Magvispeed consists of glycerophosphate magnesium and vitamins B2, B3, and B6, and is effective for muscle cramps, physical fatigue, and decreased stamina due to magnesium deficiency, as well as supporting vitamin supplementation during pregnancy and breastfeeding.
■Dong-A Pharmaceutical announced on the 12th that its official online mall Dmall will hold a customer appreciation promotion for seven days starting from the 12th, marking the fifth anniversary of its launch. Since its opening in 2020, Dmall has sold various health products from Dong-A Pharmaceutical, including Orthomol, Ailo, Morning Care, and Circulan. This event was planned to reciprocate to consumers who have shown great support for Dmall, allowing them to meet Dong-A Pharmaceutical's representative brands at reasonable prices during the event period. Notably, the male and female tailored multivitamins 'Vital M (for men)' and 'Vital F (for women)' from the German premium health functional food brand Orthomol will be offered at a 40% discount for a 30-day supply. Additionally, the inner beauty brand Ailo's new product "Mucin Collagen Jelly" and Vitagran's 100% pure juice "Organic Lemon Juice" will be available at a dramatically reduced price of 50% off.
■Daewoong Pharmaceutical announced on the 12th that it has launched "Enercisle Platinum Mega," a new lineup from its premium health functional food brand Enercisle, containing ingredients that support blood circulation, triglycerides, blood pressure, blood sugar, cholesterol, and liver health all in one product. Enercisle Platinum Mega is a 5-in-1 product that can care for blood circulation, triglycerides, blood pressure, blood sugar, and cholesterol health at once, and it features five functional ingredients (rTG Omega 3, Coenzyme Q10, banaba leaf extract, red yeast rice, and milk thistle extract), reducing the hassle and economic burden of taking multiple supplements separately.
■Ildong Pharmaceutical announced on the 12th that it has appointed model and broadcaster Lee Hyun as the new face for its "Fatigue Recovery Vitamin" Aranamin C Plus and will launch a new campaign, including TV commercials. Aranamin C Plus is an over-the-counter vitamin supplement containing eight kinds of vitamin B (vitamins B1, B2, B3, B5, B6, B7, B9, and B12) and antioxidant ingredients (vitamins C, E, and selenium), as well as minerals like zinc and iron. This product particularly contains vitamin B1 in its active form (phosphorylated thiamine), which improves physical fatigue and nerve and muscle pain, and vitamin C at 600 mg (based on one tablet) that alleviates skin pigmentation such as melasma and freckles.
■SD BIOSENSOR announced on the 12th that it has signed a sublicense agreement to transfer rapid diagnostic test (RDT) production technology to Nigerian diagnostic device manufacturer Codix Bio, in collaboration with the World Health Organization (WHO) and the Medicines Patent Pool (MPP). This agreement is part of the Health Technology Access Program (HTAP) that WHO, MPP, and SD BIOSENSOR are jointly implementing. HTAP is an international health technology cooperation model designed in response to the difficulties in medical product supply in vulnerable health regions during the COVID-19 pandemic, preparing for the next pandemic. Its key goal is to contribute to the improvement of global health equity by strengthening the diagnostic device self-sufficiency of low- and middle-income countries (LMICs) and building a sustainable medical product development and production system.
■Next Biomedical announced on the 12th that its "Nexpowder" was highlighted at the world's largest digestive disease conference (DDW 2025) held in San Diego, California. The company actively marketed the product by showcasing it through an exhibition booth and academic sessions with its global rights holder, Medtronic. Medtronic presented Nexpowder as a key exhibition product, especially promoting its use for expanding treatment of lower gastrointestinal bleeding in the U.S. market. Next Biomedical highlighted the role of Nexpowder in leading strategies for treating upper and lower gastrointestinal bleeding, sharing its clinical value and actual application cases in the field of endoscopic hemostasis.
■Daewon Pharmaceutical announced on the 12th that it has completed Phase 2 clinical trials for "DW4421 (ingredient name: Padoprazan)," which is being developed as a treatment for gastroesophageal reflux disease, and has applied for approval for the Phase 3 clinical trial plan (IND) from the Ministry of Food and Drug Safety. DW4421 is the company's fourth domestically developed potassium competitive acid secretory inhibitor (P-CAB) drug. The company previously completed the domestic Phase 2 clinical trial for this treatment in February. The Phase 2 trial was conducted on 147 patients suffering from erosive gastroesophageal reflux disease. As a result, all dose groups of DW4421 showed higher treatment rates compared to the active control group in the evaluation criteria of healing rate of mucosal damage and improvement of subjective symptoms, confirming its excellence in safety and tolerance.
■Humedix, a subsidiary of Huons Group, announced on the 12th that it has held a "Liztox Series (SEELiz) Webinar" aimed at sharing clinical expertise by treatment area. Liztox is Humedix's brand of botulinum toxin. This webinar can be viewed in the webinar zone of Bluepharm Korea, a partner company of Humedix. Medical professionals wishing to watch the webinar can easily access educational content on a web-based platform without a separate application procedure. Humedix plans to hold one additional webinar each in June and the second half of the year.
■CELL has announced on the 12th that it has entered a research cooperation agreement with global life sciences company Thermo Fisher Scientific to develop an "automated and closed manufacturing platform for iPSC-derived cell therapies" at CGT Vision Center. In April, CELL successfully administered the world's first injectable 3D iPSC cartilage spheroid (MIUChon®) in collaboration with Catholic University and Seoul St. Mary's Hospital. This research collaboration aims to establish a foundation for the automated and aseptic large-scale production of various iPSC pipelines, including artificial blood and next-generation tissue reconstruction, based on the process and quality management know-how gained from that clinical experience.
■Ybrain announced on the 12th that it has launched "Mind Digital Sleep Diary," a digital health solution that effectively supports insomnia treatment. This product quantitatively analyzes users' sleep patterns to assist hospitals in diagnosing insomnia objectively and systematically. The Mind Digital Sleep Diary is designed for users to record their sleep status from the previous night every morning at home. This minimizes memory errors for patients and allows for quantitative tracking of key sleep indicators, such as bedtime, sleep latency, and night awakening frequency.
■Korea University Ansan Hospital announced on the 12th that it held an inauguration ceremony for Seong Dong-hoon, the 21st president of Korea University Ansan Hospital, a specialist in severe trauma treatment. In his inauguration speech, President Seong stated, "Opened in 1985 with 100 beds, our hospital has now solidified its status as the only advanced general hospital in the region with 767 beds, thanks to the dedication of all staff," adding, "Now faced with the new challenges of a rapidly changing social environment and the transition of the medical system, it is a time that requires change and innovation." He pledged to readjust the direction by reflecting regional characteristics and contemporary needs, promising to lead practical and realistic changes.